A group of researchers from Washington University School of Medicine, Emory University, and an organization called Global Cures recently had their study successfully peer reviewed and published in the journal Frontiers in Pharmacology. Some prominent names in the movement to investigate low cost generic treatments for SARS-CoV-2, the virus behind COVID-19, Vikas P. Sukhatme, Angela Reiersen and others share with the world that fluvoxamine, the inexpensive generic selective serotonin reuptake inhibitor (SSRI), evidences some benefit as a treatment targeting COVID-19. One small, double-blind, placebo-controlled and randomized study indicates a benefit and that fluvoxamine serves as a possible treatment for inflammation. The study team here performed a literature review in a quest to identify the mechanism of action of this, and possibly other SSRIs that may help it become a valid COVID-19 regimen.
But what are the effects of the fluvoxamine mechanism of action? How does this impact the treatment of COVID-19? Well, the study team in their analysis did identify effects of fluvoxamine from reduction in platelet aggregation to decreased mast cell degranulation. Moreover, fluvoxamine appears to interfere with endolysosomal viral trafficking as well as regulate inositol-requiring enzyme 1α-driven inflammation while boosting melatonin levels, which when combined appear to directly introduce antiviral effects while regulating coagulopathy, and mitigating cytokine storm, all known traits of severe COVID-19.
TrialSite’s gone on the record that the federal government via the National Institutes of Health (NIH) ACTIV ( ) program should include fluvoxamine in its ongoing COVID-19 research.
With a growing recognition across American society and abroad that this pathogen will be with us for a long time, the recognition sets in that in addition to ongoing vaccination programs comes the need for safe and efficacious therapeutic treatments. Should Fluvoxamine be a valid candidate, and it would certainly appear to be completely appropriate for study now, it can be added to a number of potential treatments that should they be proven safe and efficacious, could contribute to the effective management of this pandemic.
With the recent news concerning ACTIV-6, the $155 million clinical trial sponsored by the NIH and ACTIV, TrialSite learned from credible government sources that ivermectin is near or at the top of the ACTIV-6 list and that fluvoxamine was also under consideration. Substantial evidence now in place, taxpayer dollars that have primarily funded vaccine and novel therapeutic industry research should also fund low cost generic investigations. Society will only benefit with such treatments, should they be authorized. The majority of COVD-19 cases are asymptomatic to mild-to-moderate cases and what’s needed are low cost, safe and effective treatments that allow for home care, thereby reducing disease progression and transmission.
Angela M. Reiersen, MD, MPE Department of Psychiatry, School of Medicine, Washington University in St. Louis, St. Louis, MO, United States
Vikas P. Sukhatme, MD, ScD Department of Medicine and the Morningside Center for Innovative and Affordable Medicine, School of Medicine, Emory University, Atlanta, GA, United States
Sharat J. Vayttaden, independent Researcher, Montgomery Village, MD, United States
Vidula V. Sukatme, MS, Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, United States, GlobalCures